FindMyKOL
Clinical trialNCT06100913Active, not recruitingPhase 2Interventional

Immunology of Ebola Vaccine

NCT06100913 is a phase 2 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is active and no longer recruiting. It studies Recombinant Vesicular Stomatitis Vaccine for Ebola in Ebola Virus Disease. The registry lists an enrollment of 30 participants at 2 sites in 1 country. The registry lists a start date of 6 Aug 2024 and a primary completion date of 31 Aug 2027. One of its registered investigators has a FindMyKOL profile.

SponsorEmory University →Enrollment30Ebola Virus Disease
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06100913
FieldValue
Registry IDNCT06100913
StatusActive not recruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorEmory University
Enrollment30
Registered sites2
Countries1
ConditionsEbola Virus Disease
DrugsRecombinant Vesicular Stomatitis Vaccine for Ebola
Start6 Aug 2024
Primary completion31 Aug 2027
Study completion31 Aug 2027
Last update posted22 Jan 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

In this study 30 healthy adult participants will receive a single dose of an Ebola vaccine. Blood samples, fine needle aspirates, core biopsies, and bone marrow aspirates will be collected prior to and following vaccination to assess immune responses in the blood, lymph nodes, and bone marrow over multiple time points.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States1 site
  • the Hope Clinic of the Emory Vaccine Center

    Decatur

Missouri, United States1 site
  • Washington University in St. Louis

    St Louis

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouri: 1 siteMO1KentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 siteGA1HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Recombinant Vesicular Stomatitis Vaccine for Ebola
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06100913

Each answer restates registry values shown on this page.

What is NCT06100913?

NCT06100913 is a phase 2 interventional trial sponsored by Emory University. It studies Recombinant Vesicular Stomatitis Vaccine for Ebola in Ebola Virus Disease.

Is NCT06100913 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT06100913?

The registry names Ali Ellebedy, PhD (study chair, Washington University School of Medicine) and Nadine Rouphael, MD (principal investigator, Emory University) as overall officials.

Where does NCT06100913 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06100913 study?

The registered drug and biological interventions are Recombinant Vesicular Stomatitis Vaccine for Ebola.

When is NCT06100913 expected to complete?

The registry lists a primary completion date of 31 Aug 2027 and a study completion date of 31 Aug 2027. The sponsor last updated the record on 22 Jan 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.